-
Mar. 13, 2024
Announcements
"Investors' Meeting for the DX Strategy" has been released.
-
Feb. 5, 2024
Announcements
"Investors' Meeting for FY2023 3rd Quarter Financial Results" has been released.
-
Feb. 2, 2024
IR
Notice Concerning Finance Expense (Foreign Exchange Loss)
-
Feb. 2, 2024
IR
Sumitomo Chemical Announces Revisions to Its Financial Forecast and Projected Dividend for the Full Year Ending March 31, 2024
-
Feb. 2, 2024
IR
Summary of Consolidated Financial Results for Third Quarter Fiscal Year 2023
-
Nov. 2, 2023
Announcements
"Investors' Meeting for FY2023 1st Half Financial Results, Management Priorities and Business Strategies" has been released.
-
Nov. 1, 2023
IR
Sumitomo Chemical Announces Revisions to Its Financial Forecast for the Full Year Ending March 31, 2024
-
Nov. 1, 2023
IR
Summary of Consolidated Financial Results for Second Quarter Fiscal Year 2023
-
Oct. 27, 2023
IR
Sumitomo Chemical Announces Impairment Loss and Revisions to Its Financial Forecast for the Half-Year Ended September 30, 2023
-
Sep. 29, 2023
Announcements
Annual Report 2023 has been published
-
Aug. 2, 2023
IR
Notice Concerning Finance Income
-
Aug. 2, 2023
IR
Summary of Consolidated Financial Results for First Quarter Fiscal Year 2023
-
Jul. 20, 2023
IR
Notice Regarding Payment Completed of New Shares as Restricted Stock Compensation
-
Jun. 23, 2023
Announcements
"Initiatives aimed at enhancing corporate value" has been published in Investor Relations
-
Jun. 21, 2023
IR
Notice Regarding Issuance of New Shares as Restricted Stock Compensation
-
Jun. 19, 2023
Announcements
Osaka Works and Research Laboratories version has been released on the Virtual Plant Tour in "To Our Investors"
-
May. 31, 2023
Announcements
Investors' Handbook 2023 has been published
-
May. 23, 2023
Announcements
Notice of the 142nd Ordinary General Meeting of Shareholders has been published.
-
May. 16, 2023
Announcements
"Investors' Meeting for FY2022 Financial Results, Management Priorities and Business Strategies" has been released.
-
May. 15, 2023
IR
Announcement of Impairment Loss